ALXN (7/24/11, +37.33%)
GNC (2/19/12, +0.00%)
ULTA (11/13/11, +14.11%)
LQDT (12/25/11, +17.43%)
NUS (8/28/11, +40.57%)
MA (9/24/11, +17.50%)
DLTR (9/4/11, +25.47%)
MNST (10/16/11, +12.75%)
CXO (1/29/12, +7.65%)
GWW (1/15/12, +6.19%)
CFX (2/12/12, +6.29%)
TJX (2/12/12, +1.48%)
Additions:
GNC (2/19/12, +0.00%)
Subtractions:
AAP (12/11/11, +21.76%)
AUY (1/8/12, +9.79%)
DG (9/4/11, +17.53%)
GOLD (12/11/11, +2.34%)
Last week, the major U.S. indexes resumed their upward trend. The Nasdaq advanced 1.6%, the NYSE composite added 1.5%, the S&P 500 gained 1.4%, and the Dow moved up 1.2% The IBD outlook remains at “confirmed uptrend”. The markets flashed some signs of distribution but not enough to put the current uptrend under pressure. It’s still okay to make new purchases but keep in mind that this rally is starting to get long in the tooth and some type of pullback wouldn’t be all that surprising to see.
This week, two watch list stocks are at or near proper buy points. MA, trading at $396.00, is still within 5% of a $385.09 buy point after breaking out of a 2nd stage flat base. DLTR, trading at $89.35, is still within 5% of a $86.74 buy point off of a three weeks tight pattern.
/as usual, your mileage may vary, always do your own homework
Filed under: Blog Entry Tagged: | IBD, Investing, Investors Business Daily, Stocks, Watch List
